Tomopenem (formerly CS-023) is a carbapenem β-lactam antibiotic.[1]

Tomopenem
Names
IUPAC name
(4R,5S,6S)-3-[(3S,5S)-5-[(3S)-3-[[2-(diaminomethylideneamino)acetyl]amino]pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Identifiers
3D model (JSmol)
ChemSpider
KEGG
UNII
  • InChI=1S/C23H35N7O6S/c1-10-17-16(11(2)31)21(34)30(17)18(22(35)36)19(10)37-13-6-14(28(3)9-13)20(33)29-5-4-12(8-29)27-15(32)7-26-23(24)25/h10-14,16-17,31H,4-9H2,1-3H3,(H,27,32)(H,35,36)(H4,24,25,26)/t10-,11-,12 ,13 ,14 ,16-,17-/m1/s1
    Key: KEDAXBWZURNCHS-GPODMPQUSA-N
  • C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](N(C3)C)C(=O)N4CC[C@@H](C4)NC(=O)CNC(=N)N)C(=O)O)[C@@H](C)O
Properties
C23H35N7O6S
Molar mass 537.64 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

References

edit
  1. ^ Sugihara, K.; Tateda, K.; Yamamura, N.; Koga, T.; Sugihara, C.; Yamaguchi, K. (2011). "Efficacy of human-simulated exposures of tomopenem (Formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection". Antimicrobial Agents and Chemotherapy. 55 (11): 5004–5009. doi:10.1128/AAC.00068-11. PMC 3195026. PMID 21844314.5004-5009&rft.date=2011&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195026#id-name=PMC&rft_id=info:pmid/21844314&rft_id=info:doi/10.1128/AAC.00068-11&rft.aulast=Sugihara&rft.aufirst=K.&rft.au=Tateda, K.&rft.au=Yamamura, N.&rft.au=Koga, T.&rft.au=Sugihara, C.&rft.au=Yamaguchi, K.&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195026&rfr_id=info:sid/en.wikipedia.org:Tomopenem" class="Z3988">